Lipid peroxidation and total antioxidant capacity in vitreous, aqueous humor, and blood samples from patients with diabetic retinopathy by Mancino, Raffaele et al.
Lipid peroxidation and total antioxidant capacity in vitreous,
aqueous humor, and blood samples from patients with diabetic
retinopathy
Raffaele Mancino,1 Donato Di Pierro,2 Chiara Varesi,1 Angelica Cerulli,1,3 Alessandra Feraco,2
Claudio Cedrone,1 Maria Dolores Pinazo-Duran,4 Massimiliano Coletta,2 Carlo Nucci1
(The first two authors contributed equally to this work)
1Ophthalmology Unit, Department of Biopathology, Tor Vergata University of Rome, Rome, Italy; 2Department of Experimental
Medicine and Biochemical Sciences, Tor Vergata University of Rome, Rome, Italy; 3Department of Pharmacobiology, University
of Calabria, Cosenza, Italy; 4Ophthalmic Research Unit “Santiago Grisolia”University Hospital Dr Peset, Valencia, Spain
Purpose: To evaluate levels of malondialdehyde and the total antioxidant capacity (TAC) in the blood, aqueous humor,
and vitreous bodies of diabetic and nondiabetic patients. We also measured the blood energy charge potential (ECP).
Methods: We examined 19 patients with type 2 diabetes mellitus and diabetic retinopathy. Ten were scheduled for cataract
surgery and pars plana vitrectomy because of proliferative diabetic retinopathy (PDR). The other nine, with mild
nonproliferative PDR (NPDR), and fourteen nondiabetic, age-matched subjects enrolled as a control group were scheduled
for cataract surgery and vitrectomy because of epiretinal membranes. Blood, aqueous humor and vitreous body samples
were collected at the time of surgery. Malondialdehyde concentrations and blood ECP were measured with high-
performance liquid chromatography. The TAC of the samples was estimated with the oxygen radical absorbance capacity
method.
Results: The level of blood and vitreous malondialdehyde in the PDR group was significantly higher compared to controls
and to NPDR patients. PDR patients also had lower levels of TAC at the vitreous body and aqueous humor level, but not
at the blood level, compared to controls and with NPDR patients. In all diabetic patients, the blood ECP values were
significantly lower, compared to control subjects.
Conclusions: Our data support the hypothesis that oxidative stress and the decrease of antioxidant defenses are associated
with the progression of diabetic retinopathy to its proliferative form. Antioxidant supply may have the effect of correcting
oxidative stress and inhibiting disease progression.
In vitro and in vivo studies suggest that oxidative stress
is increased in diabetes and that this plays an important role
in the pathogenesis of diabetic complications, including
retinopathy. Increased superoxide levels have been
demonstrated in the retinas of diabetic rats and in retinal cells
incubated in high-glucose media [1,2]. The retinas of rats with
experimentally induced diabetes also display more extensive
membrane lipid peroxidation and oxidative DNA damage,
which are the consequences of reactive oxygen species
(ROS)-induced injury [1,3-5]. Interestingly, oxidative stress
contributes not only to the onset of diabetic retinopathy, but
also to its persistence after glycemic control has been
reestablished. This phenomenon, which is referred to as
“metabolic memory” [6], has been attributed to the
accumulation of damaged molecules and ROS that are not
easily eliminated by the restoration of normoglycemia.
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Oxidative stress reflects excess formation and/or
impaired removal of ROS. Therefore, adequate levels of the
antioxidant enzymes responsible for scavenging free radicals
are essential for redox homeostasis. Retinal levels of enzymes
such as superoxide dismutase (SOD), glutathione reductase,
glutathione peroxidase, and catalase are decreased in animals
with experimentally induced diabetes [3,7]. As a
consequence, intraretinal levels of the potent antioxidant,
glutathione, are also decreased in diabetic rats [8]. In humans,
Pan et al. [9] measured oxidative stress parameters in the
blood, and their findings strengthen the hypothesis that an
increased presence of oxidative species contributes to the
onset and advancement of diabetic retinopathy. However,
apart from this interesting study, very little research has been
done on the oxidative and antioxidant capacities of body fluids
in patients with diabetes or on how these capacities correlate
with the stage of the disease.
To address this issue, we analyzed samples of blood and
aqueous and vitreous humors from diabetic patients with
proliferative and nonproliferative forms of retinopathy and
nondiabetic controls. Each specimen was subjected to high
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performance liquid chromatography (HPLC) to determine
levels of malondialdehyde (MDA), which is produced during
phospholipid peroxidation [10] and the activation of the
arachidonate cycle [11]. MDA is widely regarded as a marker
of peroxidative damage to cell membranes induced by
physical or chemical oxidative stress [12]. The total
antioxidant capacity (TAC) of each sample was also
determined with the oxygen radical absorbance capacity
(ORAC) method and according to energy charge potential
(ECP), a biomarker of tissue energy status that was assessed
in blood samples.
METHODS
The study was approved by the institutional review board of
the University Hospital Tor Vergata. The study followed the
tenets of the Declaration of Helsinki. All participants provided
informed consent after receiving an explanation of the nature
and possible consequences of the study. The study group
consisted of 19 patients with type 2 diabetes mellitus (nine
males and ten females; mean age: 72±1.7 years) recruited
from the Ophthalmology Unit of the Tor Vergata University
of Rome Medical Center. All diagnoses of type 2 diabetes
were based on criteria recommended by the World Health
Organization, and all patients were being treated with dietary
measures and insulin. Retinopathy was classified by an
independent ophthalmologist using fundus photography and
fluorangiographic imaging. On the basis of his findings,
patients were divided into two groups. Group 1 included ten
patients with mild nonproliferative retinopathy (NPDR), and
group 2 consisted of nine patients with proliferative
retinopathy (PDR). The mean duration of diabetes for NPDR
and PDR patients was 16.9±4.2 years and 21.3±6.1 years
respectively. For comparison purposes, we also enrolled a
control group consisting of 14 age-matched nondiabetic
subjects (6 males and 8 females, mean age 70±2.1 years).
Group 1 patients and control subjects were scheduled for
cataract surgery and vitrectomy to eliminate epiretinal
membranes, with or without macular holes. Group 2 patients
were scheduled for cataract surgery and pars plana vitrectomy
for long-standing (>3 months) or recurrent vitreous or
preretinal hemorrhage, or for tractional retinal detachment
involving or threatening the macula. In this group, laser
photocoagulation was performed at an earlier stage of the
disease (but not in the preceding three months) in all patients.
Study candidates were excluded for any of the following
reasons: smoking, glaucoma, liver disease, severe
nephropathy, cancer, collagen diseases, acute or chronic
infections, fever, congestive heart failure, or use of oral
antioxidant supplements.
Sample collection: Samples of blood, aqueous humor,
and vitreous were collected from all participants on the day of
surgery. Venous blood samples were drawn after an overnight
fast. The samples were placed on ice and centrifuged within
1 h (2,800× g at 4 °C for 15 min), and the supernatants were
stored at −20 °C until analyzed. Aqueous humor samples (0.1–
0.2 ml) were rapidly collected at the beginning of cataract
surgery with a 27-gauge needle on a tuberculin syringe.
Special care was taken to avoid blood contamination. Samples
were immediately cooled and stored at −70 °C. Vitreous
humor (300–400 μl) was collected from each patient before
infusion started. Samples were placed in individual cryo-
Eppendorf tubes, stored at −70 °C, and assayed within 2 weeks
of collection.
Quantitative analysis of malondialdehyde and energy
state: Blood, aqueous humor, and vitreous samples were
collected in sterile tubes. Ice-cold 1.2 M HClO4 (1:2, w/w)
was added to the blood samples to deproteinize erythrocytes.
All samples were centrifuged at 20,690× g for 10 min at 4 °C,
neutralized by adding 5 M K2CO3 in ice, filtered through a
0.45 μM Millipore-HV filter (Millipore Corporation,
Billerica, MA), and subjected to HPLC. The ion-pairing
method was used for simultaneous direct determination of
MDA and adenine nucleotide levels in 100 μl of a perchloric
acid extract from each sample [12]. We used a Vydac
250×4.6 mm, 5-μm particle size column with its own guard
column (Eka Chemicals AB, Bohus, Sweden) and
tetrabutylammonium hydroxide as the ion-pairing reagent.
Briefly, metabolites were separated by creating a step gradient
(adapted to the column size [12] with two buffers: buffer A
was 10 mM tetrabutylammonium hydroxide, 10 mM
KH2PO4, 0.25% methanol, pH 7.00; buffer B was 2.8 mM
tetrabutylammonium hydroxide, 100 mM KH2PO4, 30%
methanol, pH 5.50). The gradient was 10 min, 100% buffer
A; 3 min, 90% buffer A; 10 min, 70% buffer A; 12 min, 55%
buffer A; 15 min, 45% buffer A; 10 min, 25% buffer A; and
5 min, 0% buffer A. A flow rate of 1.2 ml/min was maintained
throughout each run, and the column temperature was
maintained at 23 °C with the aid of water-jacketed glassware.
The HPLC apparatus consisted of a Surveyor LC Pump
(ThermoFinnigan Italia, Rodano, Milan, Italy) connected to a
Surveyor PDA Detector (ThermoFinnigan Italia) with a
wavelength range of 200–300 nm. Data were acquired and
analyzed with the ChromQuest program (ThermoQuest,
Milan, Italy). Areas, retention times, and absorbance spectra
of the peaks of sample chromatograms were compared with
those of freshly prepared ultrapure standards, to determine the
concentration of the various compounds at 267 nm (the upper
limit of the MDA absorbance spectrum) and to identify
different metabolites. Hemoglobin and the percentage of
hemolysis were calculated with standard techniques [13] in a
Jasco-685 double-beam spectrophotometer (Jasco Europe,
Lecco, Italy). Briefly, Hb concentration was determined by
adding 20 μl of whole blood to 5 ml of Drabkin reactive and
measuring the absorbance at 540 nm. The percentage of
hemolysis was determined adding 50 μl of heparinized whole
blood to 5 ml NaCl 0.9% buffered at pH=7.4 and measuring
the absorbance at 540 nm.
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The blood energy-state levels were determined
employing ATP, ADP, and AMP (detected by HPLC), and
and the ECP was calculated according to the following
formula: ECP=ATP+0,5 ADP/ΣNT, where ΣNT (=ATP
+ADP+AMP) is the sum of the adenine nucleotide levels
[14].
Oxygen radical absorbance capacity assay: The oxygen
radical absorbance capacity (ORAC) assay is based on the
dose- and time-dependent decrease in the fluorescence
intensity of β-phycoerythrin (β-PE) when oxidized by oxygen
radicals [15]. It measures the antioxidant capacity of a
substance—blood, vitreous, and aqueous humor in this case
—in terms of its ability to inhibit or delay β-PE peroxidation.
Our assay was performed with the original method [16],
with a few modifications [17]. AAPH [2,2’-Azobis(2-
aminopropane)dihydrochloride] purchased from Polyscience
(Warrington, PA) was used as the free radical generator, and
β-PE was purchased from Sigma-Aldrich (St. Louis, MI). The
final reaction mixture (2 ml) contained 1.750 ml of 75 μM
phosphate buffer (pH 7.0) plus 0.100 ml of one of the
following: 20 μM trolox (6-hydroxy-2,5,7,8-tetramethyl-2-
carboxylic acid), which was used as the standard; a body fluid
sample (blood, aqueous humor, or vitreous); or buffer alone
(used as the reference). Beta-phycoerythrin (0.100 ml of a
34 mg/l solution) was placed in each well, and the oxidant
reaction was started by adding 160 mM (0.050 ml per well)
AAPH. Beta-PE fluorescence was measured with a Varian
Cary Eclipse Fluorescence Spectrofotometer (Varian
Australian PTY LTD, Victoria, Australia) at λ=546 nm (λ
excitation) and λ=573 nm (λ is emission). Measurements were
made every 2.5 min at 37 °C for 1 h or until the fluorescence
variation dropped below 2%.
The ORAC of the sample was expressed as micromol
trolox equivalents /g and calculated as ([As − Ab]/[At − Ab])
ka, where As is the area under the curve (AUC) of β-PE in the
sample calculated with the Origin 2.8 integrating program
(Microcal Software), At is the AUC of the trolox, Ab is the
AUC of the control, k is the dilution factor (1:500 for the
blood, 1: 100 for aqueous humor, 1:50 for vitreous), and a is
the concentration of the trolox in mmol/l.
Statistical analysis: Statistical analysis of differences
between groups was performed with the ANOVA (ANOVA)
test. Significance was set at p<0.05.
RESULTS
As shown in Figure 1, blood MDA levels in diabetic patients
were significantly increased over those of control patients
(p<0.001), due to a highly significant increase of PDR values
versus control group and versus NPDR values (both,
p<0.001). At the level of the vitreous body, patients with PDR
again had significantly increased MDA levels, compared to
the controls (p=0.050), but there were no significant
differences between the two groups of diabetic subjects and
controls or between the NPDR subgroup of patients and
controls. The analysis of MDA levels in the aqueous humor
revealed no significant differences between any of the groups
tested.
On the whole, the control group also presented
significantly higher TACs than diabetic subgroups in both the
vitreous (p<0.001) and aqueous humors (p=0.003), but there
were no significant differences in the TACs of blood samples
from these groups (Figure 2). Similar findings emerged from
subgroup analyses. PDR patients had decreased TACs in the
vitreous and aqueous humors (but not in the plasma),
compared to control subjects (p=0.002 and p=0.003,
respectively) and with the NPDR patient subgroup (p<0.001
and p=0.032, respectively).
The ECP was measured only in the blood samples. On
the whole, the control group (mean 0.85±0.04) exhibited
significantly higher values than the NPDR and PDR groups,
(ANOVA, p=0.002). In this case, the PDR and NPDR
subgroups were not significantly different from one another,
and both exhibited mean ECPs (NPDR patients, 0.80±0.05;
PDR patients, 0.79±0.07) that were significantly lower than
the control values (p=0.012 and p=0.016, respectively).
DISCUSSION
In this study, we attempted to characterize the oxidative stress
and the total antioxidant capacities of blood and aqueous and
vitreous humors in diabetic patients with or without
proliferative retinopathy. Interestingly, in patients undergoing
vitrectomy for PDR, levels of MDA in the blood and vitreous
body (but not in the aqueous humor) were significantly higher
than those found in nondiabetic controls and in diabetic
patients with NPDR. Oxidants are highly reactive compounds
with half-lives of a few seconds, and this seriously hinders
their measurement in vivo [9]. However, many biomarkers
have been developed to evaluate oxidative stress, including
the breakdown products of peroxidized polyunsaturated fatty
acids, such as MDA, which has proved to be both sensitive
and reliable for this purpose [18]. Ion-pairing HPLC
performed with tetrabutylammonium allows the simultaneous
measurement of all nucleotides and corresponding
deoxynucleosides with no chemical manipulation of samples
other than perchloric acid deproteinization. This approach
minimizes the risk that metabolite concentrations will be
altered, and it provides clear, reliable, reproducible
information on peroxidative damage and energy metabolism,
both of which are important parameters in studies of ischemia
and reperfusion injury [19]. Increased serum levels of MDA
and conjugated dienes have been found in patients with
diabetes [20], and in a recent study [9], serum MDA
concentrations measured spectrophotometrically using a
thiobarbituric acid-reacting substrate were found to be higher
in patients with PDR than in those with NPDR or in healthy
controls.
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Our study is the first to use HPLC to explore this issue,
and our findings confirm these previous reports on blood
MDA, and extend this observation to the vitreous body. This
suggests that high blood levels of MDA in diabetic patients
reflect similar increases at the level of the vitreous body, and
it points to the probable involvement of oxidative stress and
lipid peroxidation in the progression of diabetic retinopathy
to the proliferative form. In accordance with this hypothesis,
we also found that patients with PDR had markedly reduced
TACs at the levels of the vitreous (−80% versus controls) and
aqueous (−40%) humors. Because it is relatively difficult to
measure individual antioxidants separately, specific assays
have been designed to measure the overall oxygen radical-
scavenging capacity of fluid samples. The ORAC assay has
been found to provide a good index of the total antioxidant
capacity in patients with diabetes. Studies have shown that the
plasma ORAC is reduced in diabetic patients in general, and
patients with complications such as coronary artery disease
and renal failure have lower values than those without
complications [21]. However, reduced blood ORAC values
are strongly associated with poor glycemic control in DM
patients [21,22], and this may explain why the ORACs
observed in our patients (with or without retinopathy) were
not significantly different from those of the nondiabetic
controls. Verdejo et al. also suggested that antioxidant
defenses in the vitreous body were depressed in patients with
PDR. Their conclusion was based on the results of assays of
SOD activity and catalase levels [23], but the retina has several
other mechanisms for minimizing oxidative stress, including
those involving low molecular weight scavengers (i.e., α-
tocopherol, glutathione, and ascorbic acid) and other enzymes
like glutathione peroxidase [24]. In addition, every
antioxidant system can exert its activity with different
mechanisms and different efficiency, according to its
chemical structure and the stage of the disease. For this reason,
the TAC might be much more important than the
concentration of single antioxidants. However, Izuta et al.
[25] recently reported that the TAC of the vitreous is actually
increased in patients with PDR. Their findings were not
obtained with the ORAC assay we used with a PAO test,
which provides quantitative estimates of the antioxidant
capacity of a biologic fluid based on the reduction of Cu2+.
Interestingly, we also observed a reduced TAC in the
aqueous humor of patients with PDR. Recent studies have
demonstrated a close correlation between oxidative stress and
morphological changes in the trabecular meshwork [26-28],
suggesting that anterior chamber involvement in patients with
PDR may be caused partly by redox-state imbalances.
Figure 1. Malondialdehyde (MDA)
levels in the blood, aqueous humor and
vitreous of diabetic patients and
controls. The levels of MDA were
measured by High Performance Liquid
chromatography in the blood, aqueous
humor and vitreous of the control (white
columns), non-proliferative diabetic
retinopathy (NPDR; gray columns) and
proliferative diabetic retinopathy (PDR;
black columns) groups. Blood MDA
levels in PDR patients were
significantly increased over those of
control and NPDR group (both,
p<0.001). In the aqueous humor no
significant differences between the
groups were found. In the vitreous body,
PDR patients, but not NPDR subjects,
had increased MDA levels as compared
with controls (p=0.050). Data are
expressed in µmol/ml and represent
mean±standard deviation (bars).
ANOVA test was used.
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Finally, the blood of our diabetic patients exhibited
significantly reduced energy charge potentials, compared to
controls, and interestingly enough, this difference was not
limited to the patients with proliferative retinopathy. The ECP
represents the balance between energy-producing and energy-
consuming reactions, and decreased values generally reflect
insufficient production of ATP via the oxidative and
phosphorylative activities of the mitochondria. Our finding
indicates that in diabetic patients, the blood energy supply is
deficient even before the onset of retinopathy, and its
reduction may be a primary event in the development of the
complications associated with the disease.
On the whole, these data indicate that alteration of the
redox state and the energy potential contribute to the
development of diabetic retinopathy, although the
mechanisms by which oxidative stress triggers this event have
not been fully elucidated. Oxidative stress not only creates a
vicious cycle of damage to membrane lipids, proteins, and
DNA, it also amplifies ROS production by also activating
other metabolic pathways that are involved in the
development of diabetic retinopathy [8]. These include the
polyol pathway [29], the protein kinase C pathway [30,31],
the hexosamine biosynthesis pathway [32], and the advanced
glycation end product pathway [33], the last of which has been
implicated in basement-membrane thickening [34] and the
loss of pericytes and endothelial cells that it causes. ROS are
also known to promote the breakdown of the blood-retinal
barrier and to alter retinal blood flow by modulating
production of vasoactive effector molecules such as
endothelin-1 [35]. In addition, oxidative stress also
upregulates the retinal expression of VEGF [36] and mediates
the hyperglycemia-induced effects of VEGF that give rise to
the microvascular complications of diabetes [37]. Recently,
Izuta [25] found a positive correlation between N-hexanoyl-
lysine (a lipid peroxide) and VEGF concentrations in the
vitreous bodies of patients with PDR, thus confirming that
oxidative stress induced by increased ROS generation may
play a pivotal role in the upregulation of VEGF in the vitreous
body in PDR patients.
The main limitation of our study is the small number of
patients examined, which reflects difficulties in recruiting
patients with the clinical characteristics used as selection
criteria.
Taken together, our results strongly suggest that the
development of diabetic retinopathy is associated with high-
level oxidative stress and diminished antioxidant defenses.
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